Macquarie Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Macquarie Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-4,927	Closed	-$52K	–	2060
2022 Q3	$52K	Hold	4,927	–	–	﹤0.01%	1946
2022 Q2	$40K	Hold	4,927	–	–	﹤0.01%	2111
2022 Q1	$35	Buy	+4,927	New	+$52.4K	﹤0.01%	2259

Other funds holding RXRX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Macquarie Group's RXRX Position: Q4 2022 in Review

Macquarie Group sold out of Recursion Pharmaceuticals (RXRX) in Q4 2022, closing a stake of 4,927 shares — an estimated $52K sold.

Macquarie Group first reported a position in RXRX in Q1 2022 and held it in 3 quarters. The position peaked at $52K in Q3 2022. 144 funds tracked by Wall St. Rank hold RXRX as of Q4 2022.

Macquarie Group reported no remaining Recursion Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
Macquarie Group sold 4,927 Recursion Pharmaceuticals shares in Q4 2022, an estimated $52K.
Macquarie Group first reported a position in Recursion Pharmaceuticals in Q1 2022 and held it in 3 quarters.
Macquarie Group's Recursion Pharmaceuticals position peaked at $52K in Q3 2022.
144 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2022.

Based on Macquarie Group's 13F filing for Q4 2022, filed 21 Feb 2023.